Share Price, page-123

all scheduled for mid-December. official publication of US patent corrected with definition "autism" next December 14th. this inevitably fits in with the trofinetide results and responses from the company to the FDA regarding the 2591 IND suspensions. company in a field of experimentation with targeted and very ambitious objectives, where this updated patent plays a fundamental role for a highly prestigious partnership (risk of early onset of Alzheimer's disease in Prader-Willi syndrome).

https://register.epo.org/documentView?number=US.202016749185.A&documentId=1-1-US++167491851HP1+

there is now no doubt about the behavior of the market; everything is handled based on the options conversion price set at $ 1.84. this price enables, in the event of positive results of trofinetide, a portion of options to be converted into shares for executives. this requires an outflow of money to redeem the options currently in debt by the company. to the institutional market the level above $ 1.84 is certainly not convenient in an unpredictable context of an announcement for trofinetide in open markets, because it would give rise to the conversion and cancel the possibility of technically operating on the portfolio at fiscal level at levels of convenience like the current ones. in essence, we are trying not to allow the company to implement a halt trading to discount the announcement on trofinetide at closed markets and the consequent conversion of options not possible precisely, for the lower level of $ 1.84. whoever follows the market in detail every session will undoubtedly encounter these precise dynamics.